Free Trial
NASDAQ:ANIX

Anixa Biosciences Q1 2025 Earnings Report

Anixa Biosciences logo
$3.06 +0.11 (+3.73%)
As of 12:34 PM Eastern

Anixa Biosciences EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.10
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Anixa Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anixa Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, March 11, 2025
Conference Call Time
4:00PM ET

Earnings Documents

Anixa Biosciences Earnings Headlines

Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
See More Anixa Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anixa Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anixa Biosciences and other key companies, straight to your email.

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX), Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. Rather than marketing a broad portfolio of commercial products, the company concentrates on advancing novel therapies through research collaborations and clinical development.

Anixa’s cancer programs include a breast cancer vaccine intended to target alpha-lactalbumin, a protein associated with certain breast cancers. The program is being developed in collaboration with researchers at Cleveland Clinic. The company has also pursued an ovarian cancer vaccine program and cellular immunotherapy approaches, including chimeric antigen receptor T-cell (CAR-T) technologies designed to improve the treatment of solid tumors.

The company’s activities are primarily centered in the United States and are conducted through partnerships with academic and medical research institutions. Anixa was previously known as ITUS Corporation before adopting its current name. Amit Kumar, Ph.D., serves as chairman and chief executive officer.

View Anixa Biosciences Profile